SAE1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL150458	0.56	4/20
SCHEMBL191682	0.55	4/20
SCHEMBL175459	0.46	4/20
SCHEMBL155510	0.45	4/20
SCHEMBL155511	0.45	4/20
Pevonedistat (SCHEMBL192291)	1.00	3/20
Pevonedistat (SCHEMBL192875)	1.00	3/20
SCHEMBL193662	0.91	3/20
SCHEMBL192144	0.81	3/20
SCHEMBL192294	0.81	3/20
SCHEMBL192424	0.81	3/20
SCHEMBL229325	0.81	3/20
SCHEMBL229326	0.81	3/20
SCHEMBL235400	0.81	3/20
SCHEMBL192263	0.79	3/20
SCHEMBL193249	0.79	3/20
SCHEMBL193250	0.79	3/20
SCHEMBL191723	0.79	3/20
SCHEMBL191724	0.79	3/20
SCHEMBL191855	0.79	3/20

Clinical trials — most relevant to SAE1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment	PHASE2/PHASE3	RECRUITING
A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer	PHASE3	COMPLETED
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment	PHASE2	COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)	PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer	PHASE1	UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases	nan	UNKNOWN
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Study of the Effect of Innate on the Inflammatory Response to Endotoxin	nan	RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Genetic Studies of Strabismus, Congenital Cranial Dysinnervation Disorders (CCDDs), and Their Associated Anomalies	nan	RECRUITING
Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD	nan	COMPLETED
Genetic Analysis to Predict the Development of Paget's Disease	nan	ACTIVE_NOT_RECRUITING
Sialic Acid in Hepatocellular Carcinoma	nan	NOT_YET_RECRUITING
Fatty Acid Binding Proteins and Markers of Cellular Senescence in Cancer Survivors	nan	NOT_YET_RECRUITING
Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm	nan	COMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Establishment of a Prospective Clinical-biological Database	nan	RECRUITING
Study of Synapsis and Recombination in Male Meiosis and the Implications in Infertility	nan	COMPLETED
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SAE1 binder may also engage these)

Protein	Name	Similarity
Q5NVN7	—	1.000	Q5NVN7 →
A2VE14	—	1.000	A2VE14 →
Q9R1T2	—	0.996	Q9R1T2 →
Q6AXQ0	—	0.995	Q6AXQ0 →
Q5RKN4	—	0.960	Q5RKN4 →
DUS2	tRNA-dihydrouridine(20) synthase [NAD(P)+]-like	0.951	landscape →
P20595	—	0.951	P20595 →
Q4ZHR9	—	0.950	Q4ZHR9 →
O89050	—	0.947	O89050 →
Q9NVE7	—	0.946	Q9NVE7 →
Q4R4U1	—	0.946	Q4R4U1 →
P16068	—	0.946	P16068 →
Q5R5F8	—	0.945	Q5R5F8 →
Q9UL63	—	0.945	Q9UL63 →
Q3MHJ2	—	0.945	Q3MHJ2 →
P51583	—	0.944	P51583 →
O54865	—	0.944	O54865 →
Q9H1A3	—	0.944	Q9H1A3 →
GLS	Glutaminase kidney isoform, mitochondrial	0.944	landscape →
Q99PV3	—	0.944	Q99PV3 →
Q9DCL9	—	0.943	Q9DCL9 →
HDAC8	Histone deacetylase 8	0.943	landscape →
Q9EPL4	—	0.942	Q9EPL4 →
Q5RBN9	—	0.942	Q5RBN9 →
Q86XW9	—	0.942	Q86XW9 →
Q67FW5	—	0.942	Q67FW5 →
P13264	—	0.942	P13264 →
GUCY1B1	Guanylate cyclase soluble subunit beta-1 (GCS	0.942	landscape →
Q5XHZ9	—	0.942	Q5XHZ9 →
Q8R349	—	0.941	Q8R349 →